TY - JOUR
T1 - A robust machine learning framework to identify signatures for frailty
T2 - a nested case-control study in four aging European cohorts
AU - on behalf of the FRAILOMIC initiative
AU - Gomez-Cabrero, David
AU - Walter, Stefan
AU - Abugessaisa, Imad
AU - Miñambres-Herraiz, Rebeca
AU - Palomares, Lucia Bernad
AU - Butcher, Lee
AU - Erusalimsky, Jorge D.
AU - Garcia-Garcia, Francisco Jose
AU - Carnicero, José
AU - Hardman, Timothy C.
AU - Mischak, Harald
AU - Zürbig, Petra
AU - Hackl, Matthias
AU - Grillari, Johannes
AU - Fiorillo, Edoardo
AU - Cucca, Francesco
AU - Cesari, Matteo
AU - Carrie, Isabelle
AU - Colpo, Marco
AU - Bandinelli, Stefania
AU - Feart, Catherine
AU - Peres, Karine
AU - Dartigues, Jean François
AU - Helmer, Catherine
AU - Viña, José
AU - Olaso, Gloria
AU - García-Palmero, Irene
AU - Martínez, Jorge García
AU - Jansen-Dürr, Pidder
AU - Grune, Tilman
AU - Weber, Daniela
AU - Lippi, Giuseppe
AU - Bonaguri, Chiara
AU - Sinclair, Alan J.
AU - Tegner, Jesper
AU - Rodriguez-Mañas, Leocadio
N1 - Publisher Copyright:
© 2021, American Aging Association.
PY - 2021/2/18
Y1 - 2021/2/18
N2 - Phenotype-specific omic expression patterns in people with frailty could provide invaluable insight into the underlying multi-systemic pathological processes and targets for intervention. Classical approaches to frailty have not considered the potential for different frailty phenotypes. We characterized associations between frailty (with/without disability) and sets of omic factors (genomic, proteomic, and metabolomic) plus markers measured in routine geriatric care. This study was a prevalent case control using stored biospecimens (urine, whole blood, cells, plasma, and serum) from 1522 individuals (identified as robust (R), pre-frail (P), or frail (F)] from the Toledo Study of Healthy Aging (R=178/P=184/F=109), 3 City Bordeaux (111/269/100), Aging Multidisciplinary Investigation (157/79/54) and InCHIANTI (106/98/77) cohorts. The analysis included over 35,000 omic and routine laboratory variables from robust and frail or pre-frail (with/without disability) individuals using a machine learning framework. We identified three protective biomarkers, vitamin D3 (OR: 0.81 [95% CI: 0.68–0.98]), lutein zeaxanthin (OR: 0.82 [95% CI: 0.70–0.97]), and miRNA125b-5p (OR: 0.73, [95% CI: 0.56–0.97]) and one risk biomarker, cardiac troponin T (OR: 1.25 [95% CI: 1.23–1.27]). Excluding individuals with a disability, one protective biomarker was identified, miR125b-5p (OR: 0.85, [95% CI: 0.81–0.88]). Three risks of frailty biomarkers were detected: pro-BNP (OR: 1.47 [95% CI: 1.27–1.7]), cardiac troponin T (OR: 1.29 [95% CI: 1.21–1.38]), and sRAGE (OR: 1.26 [95% CI: 1.01–1.57]). Three key frailty biomarkers demonstrated a statistical association with frailty (oxidative stress, vitamin D, and cardiovascular system) with relationship patterns differing depending on the presence or absence of a disability.
AB - Phenotype-specific omic expression patterns in people with frailty could provide invaluable insight into the underlying multi-systemic pathological processes and targets for intervention. Classical approaches to frailty have not considered the potential for different frailty phenotypes. We characterized associations between frailty (with/without disability) and sets of omic factors (genomic, proteomic, and metabolomic) plus markers measured in routine geriatric care. This study was a prevalent case control using stored biospecimens (urine, whole blood, cells, plasma, and serum) from 1522 individuals (identified as robust (R), pre-frail (P), or frail (F)] from the Toledo Study of Healthy Aging (R=178/P=184/F=109), 3 City Bordeaux (111/269/100), Aging Multidisciplinary Investigation (157/79/54) and InCHIANTI (106/98/77) cohorts. The analysis included over 35,000 omic and routine laboratory variables from robust and frail or pre-frail (with/without disability) individuals using a machine learning framework. We identified three protective biomarkers, vitamin D3 (OR: 0.81 [95% CI: 0.68–0.98]), lutein zeaxanthin (OR: 0.82 [95% CI: 0.70–0.97]), and miRNA125b-5p (OR: 0.73, [95% CI: 0.56–0.97]) and one risk biomarker, cardiac troponin T (OR: 1.25 [95% CI: 1.23–1.27]). Excluding individuals with a disability, one protective biomarker was identified, miR125b-5p (OR: 0.85, [95% CI: 0.81–0.88]). Three risks of frailty biomarkers were detected: pro-BNP (OR: 1.47 [95% CI: 1.27–1.7]), cardiac troponin T (OR: 1.29 [95% CI: 1.21–1.38]), and sRAGE (OR: 1.26 [95% CI: 1.01–1.57]). Three key frailty biomarkers demonstrated a statistical association with frailty (oxidative stress, vitamin D, and cardiovascular system) with relationship patterns differing depending on the presence or absence of a disability.
KW - Biomarkers
KW - Clinical phenotype
KW - Disability
KW - Frailty
KW - Omics
UR - http://www.scopus.com/inward/record.url?scp=85101234843&partnerID=8YFLogxK
U2 - 10.1007/s11357-021-00334-0
DO - 10.1007/s11357-021-00334-0
M3 - Article
C2 - 33599920
AN - SCOPUS:85101234843
SN - 2509-2715
VL - 43
SP - 1317
EP - 1329
JO - GeroScience
JF - GeroScience
IS - 3
ER -